Two federally designated cancer centers are embarking on an unusual alliance. As reported in the Boston Globe, researchers at the David H. Koch Institute for Integrative Cancer Research at MIT and the Dana-Farber/Harvard Cancer Center in Boston plan a new alliance to offer greater collaboration with the goal of developing new treatments for glioblastoma brain cancer and pancreatic cancer.

Initial funding includes $2.6 million from foundations and philanthropists to support two years of work by four research teams. The project leaders hope to raise $50 million over the next three to five years to support multidisciplinary, multi-institutional research teams studying problems related to GBM and other cancers.


Dana Farber is near and dear to my heart as that is where my late husband Chris was treated for GBM. The Chris Elliott Fund/The Elliott Foundation has provided key research funding for the past 10 years in support of The Chris Elliott Neuro-Oncology Lab at Dana Farber — named in his honor and an important part of his legacy.


I am excited to hear about this new collaboration between the Koch Insitute at MIT and Dana-Farber that will combine the strengths of these two leading institutions in developing a cure for GBM.